tiprankstipranks
Trending News
More News >
Yunkang Group Limited (HK:2325)
:2325
Hong Kong Market
Advertisement

Yunkang Group Limited (2325) AI Stock Analysis

Compare
0 Followers

Top Page

HK:2325

Yunkang Group Limited

(2325)

Rating:52Neutral
Price Target:
HK$4.00
▲(31.15% Upside)
The overall stock score of 52 reflects significant financial challenges, including declining revenues and negative profitability, which weigh heavily on the score. Technical analysis shows some short-term bullish momentum but is not enough to offset valuation concerns due to the negative P/E ratio.

Yunkang Group Limited (2325) vs. iShares MSCI Hong Kong ETF (EWH)

Yunkang Group Limited Business Overview & Revenue Model

Company DescriptionYunkang Group Limited (2325) is a leading provider of comprehensive diagnostic testing services in China. The company operates in the healthcare sector, focusing on offering a wide range of laboratory testing services to hospitals, clinics, and other healthcare institutions. Yunkang Group is committed to providing high-quality and reliable diagnostic services, leveraging advanced technology and a robust infrastructure to meet the growing demand for medical testing in the region.
How the Company Makes MoneyYunkang Group Limited generates revenue primarily through the provision of diagnostic testing services to healthcare providers. The company's key revenue streams include fees charged for conducting various laboratory tests, which encompass a broad spectrum of medical diagnostics such as biochemical tests, immunological tests, and molecular diagnostics. Yunkang Group collaborates with hospitals and clinics, establishing long-term partnerships that contribute significantly to its earnings. The company also benefits from economies of scale due to its extensive network of laboratories and its investment in cutting-edge technology, which enhances operational efficiency and cost-effectiveness. Additionally, Yunkang Group may engage in strategic partnerships with medical institutions and technology providers to expand its service offerings and reach.

Yunkang Group Limited Financial Statement Overview

Summary
Yunkang Group Limited is facing financial headwinds with declining revenues and profitability. While the balance sheet shows manageable leverage, the weakening equity base is a concern. Cash flow remains relatively stable, but the company needs to address its profitability and operational efficiency to improve its financial health.
Income Statement
45
Neutral
The company has experienced declining revenue with a significant drop from 2022 to 2023. Gross profit margins have decreased, and the net profit margin is negative, indicating losses. The EBIT and EBITDA margins are also negative, reflecting operational challenges and inefficiencies.
Balance Sheet
50
Neutral
The company maintains a moderate debt-to-equity ratio, indicating manageable leverage. However, the decline in stockholders' equity over recent years suggests weakening financial stability. The equity ratio shows a slight decrease, highlighting potential risks in asset management.
Cash Flow
60
Neutral
The company shows positive free cash flow, indicating some operational efficiency despite declining revenue. However, the free cash flow growth rate is fluctuating, and the operating cash flow to net income ratio reflects the company's ongoing profitability challenges.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue711.88M891.50M4.37B2.04B1.35B
Gross Profit211.07M325.79M1.47B1.07B726.08M
EBITDA-668.52M25.07M619.32M524.28M382.01M
Net Income-791.68M-102.26M377.31M380.93M255.33M
Balance Sheet
Total Assets3.23B4.53B5.51B3.00B2.32B
Cash, Cash Equivalents and Short-Term Investments1.73B1.87B1.77B1.02B625.87M
Total Debt1.07B1.39B882.61M442.84M589.53M
Total Liabilities2.08B2.41B2.66B1.23B1.06B
Stockholders Equity1.14B2.33B2.84B1.78B1.24B
Cash Flow
Free Cash Flow228.38M271.63M-239.05M141.06M-86.66M
Operating Cash Flow258.84M333.84M130.33M413.26M221.08M
Investing Cash Flow354.02M-153.94M-1.45B374.49M-214.73M
Financing Cash Flow-535.63M276.48M1.29B-240.62M313.59M

Yunkang Group Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price3.05
Price Trends
50DMA
3.76
Negative
100DMA
3.62
Negative
200DMA
5.07
Negative
Market Momentum
MACD
-0.20
Positive
RSI
33.38
Neutral
STOCH
6.17
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2325, the sentiment is Negative. The current price of 3.05 is below the 20-day moving average (MA) of 3.84, below the 50-day MA of 3.76, and below the 200-day MA of 5.07, indicating a bearish trend. The MACD of -0.20 indicates Positive momentum. The RSI at 33.38 is Neutral, neither overbought nor oversold. The STOCH value of 6.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2325.

Yunkang Group Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
HK$18.14B4.94-4.00%3.36%10.19%-23.62%
54
Neutral
HK$2.31B33.92-7.51%1.08%-0.56%-323.09%
53
Neutral
HK$1.33B-18.19%-24.50%-93.44%
52
Neutral
HK$1.89B-48.48%0.66%-21.82%-700.17%
51
Neutral
HK$3.14B-2.19%5.32%89.43%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2325
Yunkang Group Limited
3.05
-5.14
-62.76%
HK:3309
C-MER Eye Care Holdings Limited
1.86
-0.45
-19.48%
HK:2251
Beijing Airdoc Technology Co. Ltd. Class H
13.19
1.81
15.91%
HK:2160
MicroPort CardioFlow Medtech Corp.
1.41
0.69
95.83%

Yunkang Group Limited Corporate Events

Yunkang Group Confirms Qualification of Joint Company Secretary
Aug 6, 2025

Yunkang Group Limited has announced that Mr. Lin Yingjia has been confirmed by the Hong Kong Stock Exchange as qualified to act as the company secretary under the Listing Rules, eliminating the need for a further waiver. Despite this qualification, the company will maintain its joint company secretary arrangement to ensure high standards of corporate governance, with Ms. Lam Chi Ching Cecilia continuing to assist Mr. Lin.

Yunkang Group Announces Board Changes with New Non-Executive Director Appointment
Aug 1, 2025

Yunkang Group Limited has announced a change in its board of directors, with Ms. Huang Luo resigning as a non-executive director effective August 1, 2025, to focus on personal endeavors. She leaves on good terms with no disagreements with the board. Concurrently, Mr. Zhang Weijie has been appointed as a non-executive director, bringing extensive experience in business management and financial oversight from his roles in various companies, including Daan Gene Co., Ltd. This change is expected to enhance the company’s governance and strategic direction.

Yunkang Group Limited Announces Board Composition and Roles
Aug 1, 2025

Yunkang Group Limited has announced the composition of its board of directors and the roles each member will play in the company’s governance. This update includes the appointment of Mr. Zhang Yong as Chairman and Executive Director, along with other directors who will serve on various committees such as the Audit, Remuneration, and Nomination Committees. This announcement is significant as it outlines the leadership structure that will guide Yunkang Group Limited’s strategic decisions and governance, potentially impacting its operational efficiency and stakeholder confidence.

Yunkang Group Limited AGM Resolutions Unanimously Approved
Jun 27, 2025

Yunkang Group Limited held its Annual General Meeting on June 27, 2025, where all proposed resolutions were unanimously approved by shareholders. The resolutions included the approval of financial statements, granting mandates for share repurchase and issuance, re-election of directors, and re-appointment of auditors. The meeting was attended by key company directors and the voting process was overseen by Tricor Investor Services Limited. The successful passage of these resolutions indicates strong shareholder support and positions the company for continued operational stability and strategic flexibility.

Yunkang Group Limited Forms Nomination Committee to Strengthen Governance
Jun 27, 2025

Yunkang Group Limited has established a Nomination Committee to ensure effective governance and compliance with the Hong Kong Stock Exchange regulations. The committee will be composed primarily of independent non-executive directors and will be responsible for reviewing the board’s structure and diversity, identifying qualified individuals for board membership, and assessing the independence of directors. This initiative is expected to enhance the company’s corporate strategy and governance practices.

Yunkang Group Limited Announces Annual General Meeting and Key Resolutions
Jun 3, 2025

Yunkang Group Limited has announced its upcoming Annual General Meeting, scheduled for June 27, 2025, in Guangzhou, China. During this meeting, shareholders will consider the company’s audited financial statements for the year ending December 31, 2024, and vote on resolutions regarding the repurchase of shares and the issuance of additional shares. These resolutions, if approved, will empower the company’s directors to manage share transactions, potentially impacting the company’s market operations and shareholder value.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 01, 2025